Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Up 58.0% in April

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 38,400 shares, an increase of 58.0% from the March 31st total of 24,300 shares. Approximately 3.2% of the shares of the stock are short sold. Based on an average trading volume of 49,500 shares, the short-interest ratio is currently 0.8 days.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals in a research note on Wednesday. They set a “hold” rating for the company.

Cyclacel Pharmaceuticals Trading Down 5.6 %

Shares of Cyclacel Pharmaceuticals stock opened at $1.51 on Friday. Cyclacel Pharmaceuticals has a 12-month low of $1.41 and a 12-month high of $13.20. The firm’s 50-day moving average price is $2.29 and its two-hundred day moving average price is $3.84.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.35) by $0.12. The firm had revenue of $0.03 million for the quarter. Equities research analysts anticipate that Cyclacel Pharmaceuticals will post -18.7 EPS for the current year.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.